Filing Details

Home > Insider Trading > Latest 13D and 13G Filings > 13G Filing (0001193125-19-040450)

Names of Reporting Persons

Frazier Healthcare VII, L.P.

Check the Appropriate Box if a Member of a Group (see instructions)

(a) ☐ (b) ☒

SEC USE ONLY

Citizenship or Place of Organization

Delaware

Accession Number:: 0001193125-19-040450
Form Type:: 13G Filing
Publication Date:: 2019-02-14 15:08:32

Filed By:: Frazier Healthcare Vii, L.p.
Company:: Nabriva Therapeutics Plc (NASDAQ:NBRV)
Filing Date:: 2019-02-14
SEC Url:: 13G Filing

Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name	Shared Voting Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Frazier Healthcare VII	3,312,546	3,312,546	3,312,546	4.9%
Frazier Healthcare VII-A	943,980	943,980	943,980	1.4%
FHM VII	4,256,526	4,256,526	4,256,526	6.4%
FHM VII	4,256,526	4,256,526	4,256,526	6.4%
James Topper	4,256,526	4,256,526	4,256,526	6.4%
Patrick Heron	4,256,526	4,256,526	4,256,526	6.4%
Alan Frazier	4,256,526	4,256,526	4,256,526	6.4%
Nader Naini	4,256,526	4,256,526	4,256,526	6.4%
Brian Morfitt	4,256,526	4,256,526	4,256,526	6.4%
Nathan Every	4,256,526	4,256,526	4,256,526	6.4%

Filing

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)*

Nabriva Therapeutics plc

(Name of Issuer)

Ordinary Shares

(Title of Class of Securities)

G63637105

(CUSIP Number)

December 31, 2018

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. G63637105

(1)

Consists of 3,312,546 Ordinary Shares held directly by Frazier Healthcare VII, L.P. FHM VII, L.P. is the general partner of Frazier Healthcare VII, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Alan Frazier, Nader Naini, Patrick Heron, James Topper, Nathan Every, and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VII, L.P.

(2)	Based on 66,982,094 Ordinary Shares that were outstanding as of October 26, 2018 as set forth in the Issuers Form 10-Q filed with the SEC on November 5, 2018.

CUSIP No. G63637105

(1)

Consists of 943,980 Ordinary Shares held directly by Frazier Healthcare VII-A, L.P. FHM VII, L.P. is the general partner of Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Alan Frazier, Nader Naini, Patrick Heron, James Topper, Nathan Every, and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the shares held by Frazier Healthcare VII-A, L.P.

(2)	Based on 66,982,094 Ordinary Shares that were outstanding as of October 26, 2018 as set forth in the Issuers Form 10-Q filed with the SEC on November 5, 2018.

CUSIP No. G63637105

(1)

Consists of 3,312,546 Ordinary Shares held directly by Frazier Healthcare VII, L.P. and 943,980 Ordinary Shares held directly by Frazier Healthcare VII-A, L.P (collectively, the FH Shares). FHM VII, L.P. is the general partner of both Frazier Healthcare VII, L.P. and Frazier Healthcare VII-A, L.P. and FHM VII, L.L.C. is the general partner of FHM VII, L.P. Alan Frazier, Nader Naini, Patrick Heron, James Topper, Nathan Every, and Brian Morfitt are the members of FHM VII, L.L.C. and therefore share voting and investment power over the FH Shares.

(2)	Based on 66,982,094 Ordinary Shares that were outstanding as of October 26, 2018 as set forth in the Issuers Form 10-Q filed with the SEC on November 5, 2018.

CUSIP No. G63637105

(1)

(2)	Based on 66,982,094 Ordinary Shares that were outstanding as of October 26, 2018 as set forth in the Issuers Form 10-Q filed with the SEC on November 5, 2018.

CUSIP No. G63637105

(1)

(2)	Based on 66,982,094 Ordinary Shares that were outstanding as of October 26, 2018 as set forth in the Issuers Form 10-Q filed with the SEC on November 5, 2018.

CUSIP No. G63637105

(1)

(2)	Based on 66,982,094 Ordinary Shares that were outstanding as of October 26, 2018 as set forth in the Issuers Form 10-Q filed with the SEC on November 5, 2018.

CUSIP No. G63637105

(1)

(2)	Based on 66,982,094 Ordinary Shares that were outstanding as of October 26, 2018 as set forth in the Issuers Form 10-Q filed with the SEC on November 5, 2018.

CUSIP No. G63637105

(1)

(2)	Based on 66,982,094 Ordinary Shares that were outstanding as of October 26, 2018 as set forth in the Issuers Form 10-Q filed with the SEC on November 5, 2018.

CUSIP No. G63637105

(1)

(2)	Based on 66,982,094 Ordinary Shares that were outstanding as of October 26, 2018 as set forth in the Issuers Form 10-Q filed with the SEC on November 5, 2018.

CUSIP No. G63637105

(1)

(2)	Based on 66,982,094 Ordinary Shares that were outstanding as of October 26, 2018 as set forth in the Issuers Form 10-Q filed with the SEC on November 5, 2018.

Item 1(a).

Name of Issuer: Nabriva Therapeutics plc

Item 1(b).

Address of Issuers Principal Executive Offices: PO Box 18387, Boulder, Colorado 80308

Item 2(a).

Name of Person Filing:

The entities and persons filing this statement (collectively, the Reporting Persons) are:

Frazier Healthcare VII, L.P. (FH-VII)

Frazier Healthcare VII-A, L.P. (FH-VIIA)

FHM VII, L.P. (FHM-VII L.P.)

FHM VII, L.L.C. (FHM-VII LLC)

James Topper (Topper)

Patrick Heron (Heron)

Alan Frazier (Frazier)

Nader Naini (Naini)

Nathan Every (Every)

Brian Morfitt (Morfitt and together with Topper, Heron, Frazier, Naini and Every, the Members)

Item 2(b).

Address of Principal Business Office or, if none, Residence:

The address and principal business office of the Reporting Persons is:

c/o Frazier Healthcare Partners

601 Union Street, Suite 3200

Seattle, Washington 98101

Item 2(c).

Citizenship:


Entities:	FH-VII	Delaware, U.S.A.
	FH-VIIA	Delaware, U.S.A.
	FHM-VII L.P.	Delaware, U.S.A.
	FHM-VII LLC	Delaware, U.S.A.

Individuals:	Topper	United States Citizen
	Heron	United States Citizen
	Frazier	United States Citizen
	Naini	United States Citizen
	Every	United States Citizen
	Morfitt	United States Citizen

Item 2(d).

Title of Class of Securities: Ordinary Shares

Item 2(e).

CUSIP Number: G63637105

Item 3.

If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:


(a)	☐	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)	☐	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)	☐	Insurance company as defined in section 3(a)19) of the Act (15 U.S.C. 78c);

(d)	☐	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)	☐	An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)	☐	An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)	☐	A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h)	☐	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)	☐	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)	☐	A non-U.S. institution in accordance with §240.13d1(b)(1)(ii)(J);

(k)	☐	Group, in accordance with §240.13d1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with §240.13d1(b)(1)(ii)(J), please specify the type of institution: ____

Item 4.

Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

(a)

Amount Beneficially Owned: See Row 9 of cover page for each Reporting Person.

(b)

Percent of Class: See Row 11 of cover page for each Reporting Person

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote: See Row 5 of cover page for each Reporting Person.

(ii)

Shared power to vote or to direct the vote: See Row 6 of cover page for each Reporting Person.

(iii)

Sole power to dispose or to direct the disposition of: See Row 7 of cover page for each Reporting Person.

(iv)

Shared power to dispose or to direct the disposition of: See Row 8 of cover page for each Reporting Person.

Item 5.

Ownership of 5 Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

Item 6.

Ownership of More than 5 Percent on Behalf of Another Person

Not applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group

Not applicable.

Item 9.

Notice of Dissolution of a Group

Not applicable.

Item 10.

Certification

Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.


Date: February 14, 2019	FRAZIER HEALTHCARE VII, L.P.
	By FHM VII, L.P., its general partner
	By FHM VII, L.L.C., its general partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: February 14, 2019	FRAZIER HEALTHCARE VII-A, L.P.
	By FHM VII, L.P., its general partner
	By FHM VII, L.L.C., its general partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: February 14, 2019	FHM VII, L.P.
	By FHM VII, L.L.C., its general partner

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: February 14, 2019	FHM VII, L.L.C.

	By:	/s/ Steve R. Bailey
		Steve R. Bailey, Chief Financial Officer

Date: February 14, 2019	By:	*
		James Topper

Date: February 14, 2019	By:	*
		Patrick Heron

Date: February 14, 2019	By:	*
		Nader Naini

Date: February 14, 2019	By:	*
		Nathan Every

Date: February 14, 2019	By:	*
		Brian Morfitt

Date: February 14, 2019	By:	*
		Alan Frazier


Date: February 14, 2019	^*By:	/s/ Steve R. Bailey
		Steve R. Bailey, as Attorney-in-Fact

This Schedule 13G was executed by Steve R. Bailey on behalf of the individuals listed above pursuant to a Power of Attorney, a copy of which was filed with the SEC on March 29, 2016.

Exhibit Index


Exhibit A* -		Agreement regarding filing of joint Schedule 13G.

*	Previously filed.